[
  {
    "ts": null,
    "headline": "Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial",
    "summary": "As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to varia",
    "url": "https://finnhub.io/api/news?id=4c044b4707d0041a4e7a506a38a503ef75791195a738b3c1c04686c43f9d8187",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740427200,
      "headline": "Latest DB-OTO Results Demonstrate Clinically Meaningful Hearing Improvements in Nearly All Children with Profound Genetic Hearing Loss in CHORD Trial",
      "id": 133186703,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "As presented at ARO, 10 of 11 children with at least one post-treatment assessment showed notable improvements in hearing Speech and development progress followed dramatic improvements in hearing in first child treated in the trial TARRYTOWN, N.Y., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have profound genetic hearing loss due to varia",
      "url": "https://finnhub.io/api/news?id=4c044b4707d0041a4e7a506a38a503ef75791195a738b3c1c04686c43f9d8187"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts",
    "summary": "We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average earnings growth, which is often fueled by innovations […]",
    "url": "https://finnhub.io/api/news?id=466a9b27878afeb432685d96c8403be7498918be6b54ea69270e8eebb68b2bfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740419174,
      "headline": "Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts",
      "id": 133186704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average earnings growth, which is often fueled by innovations […]",
      "url": "https://finnhub.io/api/news?id=466a9b27878afeb432685d96c8403be7498918be6b54ea69270e8eebb68b2bfd"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=43464f54fd397d8c1dd7022300e53c696419d4a8ad7182008722827ec955a990",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740415320,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 132886656,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=43464f54fd397d8c1dd7022300e53c696419d4a8ad7182008722827ec955a990"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis",
    "summary": "Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=ee8a69fab3dae0ec98cb78efd2a8455e4ce7ea63b58ccbeb936f4112e253be99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740390360,
      "headline": "The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis",
      "id": 133186705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Merck, Sanofi, Regeneron and Ionis are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=ee8a69fab3dae0ec98cb78efd2a8455e4ce7ea63b58ccbeb936f4112e253be99"
    }
  },
  {
    "ts": null,
    "headline": "Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN",
    "summary": "NEW YORK, Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
    "url": "https://finnhub.io/api/news?id=0ddda0d7df3517a745071c4312312c5fd31fe52f231e07dd53a5450427b51a55",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740375981,
      "headline": "Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) should contact The Gross Law Firm about pending Class Action - REGN",
      "id": 132862352,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "NEW YORK, Feb. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . ...",
      "url": "https://finnhub.io/api/news?id=0ddda0d7df3517a745071c4312312c5fd31fe52f231e07dd53a5450427b51a55"
    }
  },
  {
    "ts": null,
    "headline": "First Circuit Adopts Defense-Friendly \"But-For\" Causation Standard For AKS-Predicated FCA Claims",
    "summary": "In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of the Anti-Kickback Statute ,1  require proof that alleged...",
    "url": "https://finnhub.io/api/news?id=fafcd1a81177772033adeb7bcb8e2385da98a853ad21fb26451b814813e4a81f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740373987,
      "headline": "First Circuit Adopts Defense-Friendly \"But-For\" Causation Standard For AKS-Predicated FCA Claims",
      "id": 132862193,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "In a unanimous panel opinion filed on February 18, 2025, the First Circuit held that False Claims Act cases predicated on violations of the Anti-Kickback Statute ,1  require proof that alleged...",
      "url": "https://finnhub.io/api/news?id=fafcd1a81177772033adeb7bcb8e2385da98a853ad21fb26451b814813e4a81f"
    }
  },
  {
    "ts": null,
    "headline": "First Circuit Adopts \"But-For\" Causation Standard For False Claims Act Cases Based On Anti-Kickback Statute Violations",
    "summary": "In United States v. Regeneron Pharmaceuticals, Inc., the First Circuit joined the emerging majority view that False Claims Act claims based on violations of the Anti-Kickback Statute require a...",
    "url": "https://finnhub.io/api/news?id=1862d70beb7e8a2ea651eb5f537726426def0e980d7c04f5a074ea1992cbc57a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740359588,
      "headline": "First Circuit Adopts \"But-For\" Causation Standard For False Claims Act Cases Based On Anti-Kickback Statute Violations",
      "id": 132861043,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "In United States v. Regeneron Pharmaceuticals, Inc., the First Circuit joined the emerging majority view that False Claims Act claims based on violations of the Anti-Kickback Statute require a...",
      "url": "https://finnhub.io/api/news?id=1862d70beb7e8a2ea651eb5f537726426def0e980d7c04f5a074ea1992cbc57a"
    }
  }
]